<DOC>
	<DOCNO>NCT02155309</DOCNO>
	<brief_summary>Part 1 , pharmacokinetic ( PK ) phase , expand upon pilot study conduct Naval Medical Research Laboratory ( NAMRL ) goal determine bioavailability time Cmax large representative sample . Part 2 , efficacy phase , determine efficacy aqueous spray solution via exposure nausea-inducing stimulus .</brief_summary>
	<brief_title>Pharmacokinetic Efficacy Profile Intranasal Scopolamine Spray</brief_title>
	<detailed_description>Part 1 : The pharmacokinetic ( PK ) phase Objective : To determine bioavailability amount scopolamine absorb administration 0.2 mg intranasal scopolamine regular interval across 8 hour post- dose . Hypothesis : Detectable level Intranasal scopolamine ( INSCOP ) present subject plasma within 15 minute post-dose ; mean time Cmax ( maximum plasma concentration ) less 1.5 hr . Part 2 : The Efficacy phase Objective : To determine effectiveness , cognitive performance effect , medication side-effect profile 0.2 mg intranasal scopolamine spray motion sickness ( MS ) countermeasure . Hypothesis : The primary hypothesis INSCOP spray efficacious MS placebo , without statistically significant cognitive performance side-effects . Specifically , participant tolerate significantly provocative head tilt INSCOP condition placebo condition .</detailed_description>
	<mesh_term>Motion Sickness</mesh_term>
	<mesh_term>Scopolamine Hydrobromide</mesh_term>
	<mesh_term>Butylscopolammonium Bromide</mesh_term>
	<criteria>Males female , 18 59 year old , inclusive , good general health determine physical examination without clinically significant laboratory profile Normal weight body size , base Physical Readiness Test Body Composition Assessment ( PPRTBCA ) table Willing able comply study requirement restriction ; read sign informed consent . Known and/or document drug allergy , especially scopolamine Use investigational drug within 30 day start study Smoking use tobacco product , include `` chew '' `` snuff '' , within six month Blood donation significant blood loss within 30 day start study Significant gastrointestinal disorder , asthma , seizure disorder History narrowangle glaucoma History urinary retention problem History alcohol drug abuse Pregnancy suspect pregnancy , lactation Hematocrit value less 41 % male 37 % female Recent nasal , nasal sinus nasal mucosa surgery Use prescription , overthecounter , herbal medication past 7 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>scopolamine</keyword>
	<keyword>motion</keyword>
	<keyword>sickness</keyword>
</DOC>